4-hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition

Mitochondrion

Volumn 1, Issue 6, 2002, Pages 485-495

  Cardoso, Carla M P ^a,b   Almeida, Leonor M ^a,b   Custódio, José B A ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

4 hydroxytamoxifen; Anticancer drug; Breast cancer; Mitochondrial bioenergetics; Mitochondrial permeability transition; Oxidative stress

Indexed keywords

4 HYDROXYTAMOXIFEN; ADENOSINE DIPHOSPHATE; ANTIESTROGEN; CALCIUM ION; CYCLOSPORIN A; DRUG METABOLITE; OXYGEN; PHOSPHATE; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; TERT BUTYL HYDROPEROXIDE;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOENERGY; BREAST CANCER; CALCIUM TRANSPORT; CELL DEATH; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ELECTROPHORESIS; FEMALE; IN VITRO STUDY; INCUBATION TIME; LIVER MITOCHONDRION; MALE; MEMBRANE DEPOLARIZATION; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION SWELLING; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RAT; REPOLARIZATION; RESPIRATION CONTROL;

EID: 0036788607     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-7249(02)00034-X     Document Type: Article

References (51)

1. Bernardi, P., 1996. The permeabiliy transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim. Biophys. Acta 1275, 5-9.
2. Bernardi, P., Scorrano, L., Colonna, R., Petronilli, V., Di Lisa, F., 1999. Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur. J. Biochem. 264, 687-701.
3. Borgna, J.-L., Rochefort, H., 1981. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256, 859-868.
4. Broekemeier, K.M., Dempsey, M.E., Pfeiffer, D.R., 1989. Cyclosporine A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J. Biol. Chem. 264, 7826-7830.
5. 2+ to the mitochondrial permeability transition induced by tert-butylhydroperoxide in rat hepatocytes. Hepatology 29, 1523-1531.
6. Cardoso, C.M.P., Moreno, A.J.M., Almeida, L.M., Custódio, J.B.A., 2000. Hydroxytamoxifen inhibits the mitochondrial permeability transition in vitro. Eur. J. Med. Res. 35, P29.
7. 2+ plus prooxidants is determined by the extent of membrane protein thiol cross-linking. J. Bioenerg. Biomembr. 28, 523-529.
8. Ching, C.K., Smith, P.G., Long, R.G., 1992. Tamoxifen-associated hepatocellular damage and agranulocytosis. Lancet 339, 940.
9. Constantini, P., Chernyak, B.V., Petronilli, V., Bernardi, P., 1996. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J. Biol. Chem. 271, 6746-6751.
10. Cruz Silva, M.M., Madeira, V.M.C., Almeida, L.M., Custódio, J.B.A., 2000. Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure. Biochim. Biophys. Acta 1464, 49-61.
11. Cruz Silva, M.M., Madeira, V.M.C., Almeida, L.M., Custódio, J.B.A., 2001. Hydroxytamoxifen interaction with human erythrocyte membrane and induction of permeabilization and subsequent hemolysis. Toxicol. in Vitro 15, 615-622.
12. Custódio, J.B.A., Dinis, T.C.P., Almeida, L.M., Madeira, V.M.C., 1991. A reliable and rapid procedure to estimate drug partitioning in biomembranes. Biochem. Biophys. Res. Commun. 176, 1079-1085.
13. Custódio, J.B.A., Almeida, L.M., Madeira, V.M.C., 1993. The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes. Biochim. Biophys. Acta 1150, 1123-1129.
14. Custódio, J.B.A., Dinis, T.C.P., Almeida, L.M., Madeira, V.M.C., 1994. Tamoxifen and hydroxytamoxifen as intramembranous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity. Biochem. Pharmacol. 47, 1989-1998.
15. 2+ and inorganic phosphate. Toxicol. Appl. Pharmacol. 152, 10-17.
16. Davies, A.M., Martin, E.A., Jones, R.M., Lim, C.K., Smith, L.L., White, I.N.H., 1995. Peroxidase activation of tamoxifen and toremifene to cause DNA damage and covalently bound protein adducts. Carcinogenesis 16, 539-545.
17. Estrabrook, R.W., 1967. Mitochondrial respiratory control and the polarographic measurement of ADP/O ratios. Methods Enzymol. 10, 41-47.
18. 2+ plus prooxidants. J. Biol. Chem. 265, 19955-19960.
19. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L., Cronin, W.M., NSABP Contributors, 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86, 527-537.
20. Gornall, A.G., Bardawill, C., David, M.M., 1949. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 177, 751-756.
21. Halestrap, A.P., Wodfield, K-Y., Connern, C.P., 1997. Oxidative stress thiol reagents and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J. Biol. Chem. 272, 3346-3354.
22. Ichas, F., Mazat, J.-P., 1998. From calcium signalling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim. Biophys. Acta 1366, 33-50.
23. Jordan, V.C., 1990. Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res. Treat. 15, 125-136.
24. Kamo, N., Maratsugu, M., Hongoh, R., Kobatake, V., 1979. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenilphosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J. Memb. Biol. 49, 105-121.
25. 2+ uptake by the cardiac sarcoplasmic reticulum. Eur. J. Physiol. 440, 573-579.
26. Kemp, J.V., Adam, H.K., Wakeling, A.E., Slater, R., 1983. Identification and biological activity of tamoxifen metabolites in human serum. Biochem. Pharmacol. 32, 2045-2052.
27. 2+ is dependent on mitochondrial-generated reactive oxygen species. FEBS Lett. 378, 150-152.
28. Kowaltowski, A.J., Netto, L.E.S., Vercesi, A.E., 1998. The thiol-specific antioxidant enzyme prevents mitochondrial permeability transition. Evidence for the participation of reactive oxygen species. J. Biol. Chem. 273, 12766-12769.
29. Kowaltowski, A.J., Vercesi, A.E., Fiskum, G., 2000. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides. Cell Death Differ. 7, 903-910.
30. Kushnareva, Y.E., Sokolove, P.M., 2000. Prooxidants open both the mitochondrial permeability transition pore and a low-conductance channel in the inner mitochondrial membrane. Arch. Biochem. Biophys. 376, 377-388.
31. Lien, E.A., Ueland, P.M., Solheim, E., Kvinnsland, S., 1987. Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography. Clin. Chem. 33, 1608-1614.
32. Lien, E.A., Solheim, E., Ueland, P.M., 1991. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51, 4837-4844.
33. MacCallum, J., Cummings, J., Dixon, J.M., Miller, W.R., 1996. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J. Chromatogr. B 678, 317-323.
34. 2+ movements across biological membranes. Biochem. Biophys. Res. Commun. 64, 870-876.
35. Mauvais-Jarvis, P., Baudot, N., Castaigne, D., Banzet, P., Jutten, F., 1986. Trans-4-hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res. 46, 1521-1525.
36. McCague, R., Parr, I.B., Leclercq, G., Leung, O.-T., Jarman, M., 1990. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem. Pharmacol. 39, 1459-1465.
37. Moreno, A.J., Madeira, V.M.C., 1991. Mitochondrial bioenergetics as affected by DDT. Biochim. Biophys. Acta 1060, 166-174.
38. Nieminen, A-L., Saylor, A.K., Tesfai, S.A., Herman, B., Lemasters, J., 1995. Contribution of the mitochondrial permeability transiton to lethal injury after exposure of hepatocytes to t-butylhydroperoxide. Biochem. J. 307, 99-106.
39. Nieminen, A.-L., Byrne, A.M., Herman, B., Lemasters, J., 1997. Mitochondrial permeability transiton in hepatocytes induced by t-BuOOH: NAD(P)H and reactive oxygen species. Am. J. Physiol. 272, C1286-C1294.
40. Petit, X.P., Goubern, M., Diolez, P., Susin, A.S., Zamzami, N., Kroemer, G., 1998. Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: the impact of irreversible permeability transition. FEBS Lett. 426, 111-116.
41. Petronilli, V., Constantini, P., Scorrano, L., Colonna, R., Passamonti, S., Bernardi, P., 1994. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. J. Biol. Chem. 269, 16638-16642.
42. Pujol, H., Girault, J., Rouanet, P., Fournier, S., Grenier, J., Simony, J., Fourtillan, J.-B., Pujol, J.-L., 1995. Phase I study of percutaneous 4-hydroxytamoxifen with analyses of 4-hydroxytamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother. Pharmacol. 36, 493-498.
43. Sauvez, F., Drouin, D.S., Attia, M., Bertheux, H., Forster, R., 1999. Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats. Carcinogenesis 20, 843-850.
44. Skulachev, V.P., 1996. Why are mitochondria involved in apoptosis? FEBS Lett. 397, 7-10.
45. Suwalsky, M., Hernandez, P., Villena, F., Aguilar, F., Sotomayor, C.P., 1998. Interaction of the anticancer drug Tamoxifen with the human erythrocyte membrane and molecular models. Z. Naturforsh. (C) 53, 182-190.
46. Teplova, V., Evtodienko, Y., Odinokova, I., Kruglov, A., Kudrjavtsev, A., 2000. Suppression of mitochondrial permeability transition pore and induction of lymphoma P388 cell death by cyclosporin A. Life 50, 75-80.
47. Valle, V.G.R., Fagian, M.M., Parentoni, L.S., Meinicke, A.R., Vercesi, A.E., 1993. The participation of reactive oxygen species and protein thiols in the mechanism of mitochondrial inner membrane permeabilization by calcium plus prooxidants. Arch. Biochem. Biophys. 307, 1-7.
48. Wallace, K.B., Eells, J.T., Madeira, V.M.C., Cortopassi, G., Jones, D.P., 1997. Mitochondria-mediated cell injury. Fundam. Appl. Toxicol. 38, 23-37.
49. Wallace, K.B., Starkov, A.A., 2000. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 40, 353-388.
50. Williams, G.M., Iatroploulos, M.J., Djordjevic, M.V., Kaltenberg, O.P., 1993. The tryphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14, 315-317.
51. Zoratti, M., Szabo, I., 1995. The mitochondrial permeability transition. Biochim. Biophys. Acta. 1241, 139-176.